Sharemaestro Newsreel

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 4.9% in Tonix Pharmaceuticals Holding Corp., which includes 814,801 shares of common stock. This stake comprises 615,025 shares issuable upon the exercise of warrants. The ownership percentage is calculated based on …

Q3 Earnings Estimate for AptarGroup Issued By Zacks Research

Q3 EPS Estimates for Journey Medical Cut by HC Wainwright

Sidoti Equities Analysts Raise Earnings Estimates for Kamada

Equities Analysts Set Expectations for TCRX FY2026 Earnings

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is brief and does not contain additional details within the provided content. It is published by Investing.com, a financial markets news platform.

Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026

Quince Therapeutics announced a net loss of $75.5 million for Q2 2026, with $116 million in cash, cash equivalents, and investments as of June 30, 2026. The company completed a $115 million private placement concurrent with its acquisition of Orphai and initiated a Phase …

Form 8K Quince Therapeutics Inc For: 14 August By Investing.com

The article reports on Quince Therapeutics Inc.'s Form 8K filing for August 14th. It is a brief announcement from Investing.com, providing basic information about the filing and the company's stock performance on that day.

Anteris Technologies Global (NASDAQ:AVR) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated an "overweight" rating on Anteris Technologies Global (NASDAQ: AVR) with a $15 price target, suggesting a significant upside. Despite weaker-than-expected quarterly results and insider selling, the stock maintains a "Moderate Buy" consensus rating from analysts. The company's stock has shown some …

Insider Spends US$141k Buying More Shares In Embecta

Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low …

Embecta Corp. SVP Elguicze purchases $93,360 in common stock

Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase …

Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 3,029,500 Common Shares in Cybin Inc., which includes 969,500 shares issuable upon the exercise of warrants. This stake represents 4.8% of Cybin's outstanding Common Shares, based on 61,984,078 shares as of …

GTBP: Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026

GT Biopharma (GTBP) reported a narrowed net loss of $4.5 million in Q2 2026, a significant improvement from $30.2 million year-over-year, attributed to the absence of a prior non-recurring liability. The company is advancing two TriKE® candidates in Phase 1 trials, with updates anticipated …

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

HC Wainwright Has Bearish Estimate for DTIL Q3 Earnings

Delcath Systems updates bylaws to designate Delaware courts as exclusive forum

Delcath Systems, Inc. (NASDAQ:DCTH) has amended its bylaws to designate Delaware courts as the exclusive forum for internal corporate claims and federal district courts for claims under the Securities Act of 1933. This decision follows a recommendation from its Nominating and Corporate Governance Committee. …

Form 8K Delcath Systems Inc For: 14 August By Investing.com

This article announces the filing of a Form 8K by Delcath Systems Inc. on August 14th. It is a brief news item from Investing.com, providing basic information about the regulatory filing.

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026

Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …

Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com

This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …

Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 5.0% in AnaptysBio, Inc. (ANAB) common stock, as detailed in a Schedule 13G/A filing. This stake amounts to 1,491,959 shares, based on 29,608,481 shares outstanding as of June 22, 2026. The …

HC Wainwright Brokers Lower Earnings Estimates for Liquidia

HC Wainwright has lowered its Q3 2026 EPS estimate for Liquidia to $1.01 from $1.15, despite the company reporting explosive revenue growth of 1,842.1% year-over-year, driven by YUTREPIA sales. While Liquidia's EPS of $0.74 slightly missed consensus, analyst sentiment remains generally positive with a …

Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, has filed an amended Schedule 13G/A disclosing a beneficial ownership of 3.64% in MBX Biosciences (MBX). This group collectively holds 1,732,569 shares of common stock as of June 30, …

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Kyverna Therapeutics (NASDAQ:KYTX) to a loss of $0.66 per share, an improvement from its previous forecast of a $0.78 loss. The firm maintained a "Buy" rating and a $25.00 price target for the stock. …

VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M

* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …

Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53

* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …

Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones

Crinetics Pharmaceuticals announced significant progress in its planned acquisition by Vertex Pharmaceuticals, with the Hart-Scott-Rodino waiting period expiring and antitrust approvals secured in Austria, Germany, and Australia. The merger's completion hinges on Crinetics shareholder approval at a meeting on August 28, 2026, with an …

Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s

[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer’s disease through positron emission tomography (PET). Specifically, the approval allows the …

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright

Zacks Research Has Optimistic Outlook of WST Q3 Earnings

Zacks Research has updated its Q3 2026 earnings per share (EPS) estimate for West Pharmaceutical Services (NYSE: WST) to $2.14, maintaining a "Hold" rating. This optimistic outlook follows West Pharmaceutical's recent strong quarterly performance, where the company exceeded earnings and revenue expectations and raised …

Q3 Earnings Forecast for Neurogene Issued By HC Wainwright

What is HC Wainwright's Forecast for MIST Q3 Earnings?